Medizinische Universität Graz - Research portal
Selected Publication:
Stoschitzky, K; Koshucharova, G; Zweiker, R; Maier, R; Watzinger, N; Fruhwald, FM; Klein, W.
Differing beta-blocking effects of carvedilol and metoprolol.
Eur J Heart Fail. 2001; 3(3):343-349
Doi: 10.1016/S1388-9842(01)00126-X
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Stoschitzky Kurt
- Co-authors Med Uni Graz
- Fruhwald Friedrich
- Maier Robert
- Watzinger Norbert
- Zweiker Robert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Metoprolol is a beta(1)-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockades of alpha(1)-adrenoceptors. Administration of metoprolol has been shown to cause up-regulation of beta-adrenoceptor density and to decrease nocturnal melatonin release, whereas carvedilol lacks these typical effects of beta-blocking drugs. AIMS: To compare beta-blocking effects of metoprolol and carvedilol when applied orally in healthy subjects. Methods: We investigated the effects of single oral doses of clinically recommended amounts of metoprolol (50, 100 and 200 mg) and carvedilol (25, 50 and 100 mg) to those of a placebo in a randomised, double-blind, cross-over study in 12 healthy male volunteers. Two hours after oral administration of the drugs heart rate and blood pressure were measured at rest, after 10 min of exercise, and after 15 min of recovery. RESULTS: Metoprolol tended to decrease heart rate during exercise (-21%, -25% and -24%) to a greater extent than carvedilol (-16%, -16% and -18%). At rest, increasing doses of metoprolol caused decreasing heart rates (62, 60 and 58 beats/min) whereas increasing doses of carvedilol caused increasing heart rates (62, 66 and 69 beats/min), 50 and 100 mg carvedilol failed to differ significantly from the placebo (71 beats/min). CONCLUSIONS: We conclude that clinically recommended doses of carvedilol cause a clinically relevant beta-blockade in humans predominantly during exercise where it appears to be slightly (although not significantly) less effective than metoprolol. On the other hand, the effects of carvedilol on heart rate at rest appear rather weak, particularly in subjects with a low sympathetic tone. This might be caused by a reflex increase on sympathetic drive secondary to peripheral vasodilation resulting from the alpha-blocking effects of the drug. These results might be helpful in explaining why carvedilol, in contrast to metoprolol, may fail to cause up-regulation of beta-adrenoceptor density and does not decrease nocturnal melatonin release. This, in turn, may be a reason for the weak side-effects of carvedilol resulting from the beta-blockade. In addition, our data might be of interest in the interpretation of the forthcoming results of the COMET trial, although it has to be emphasised that they were derived from healthy subjects and, therefore, cannot be directly extrapolated to patients with heart failure.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Adrenergic beta-Antagonists - administration and dosage
- Adult - administration and dosage
- Blood Pressure - drug effects
- Carbazoles - administration and dosage
- Cross-Over Studies - administration and dosage
- Double-Blind Method - administration and dosage
- Exercise Test - methods
- Heart Failure - drug therapy
- Heart Rate - drug effects
- Humans - drug effects
- Male - drug effects
- Metoprolol - administration and dosage
- Middle Aged - administration and dosage
- Propanolamines - administration and dosage
- Reference Values - administration and dosage
- Find related publications in this database (Keywords)
- carvedilol
- metoprolol
- beta-blockers
- heart failure
- melatonin